Alder BioPharmaceuticals® Appoints Erin Lavelle to Newly Created Role of Chief Operating Officer
April 16 2018 - 8:30AM
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) (“Alder” or the
“Company”), a biopharmaceutical company focused on developing novel
therapeutic antibodies for the treatment of migraine, today
announced it has appointed Erin Lavelle to the newly created role
of Chief Operating Officer, effective April 16, 2018.
Ms. Lavelle brings to Alder 20 years of cross-functional
experience leading strategic and operational initiatives in the
biopharmaceutical industry. She will be responsible for leading the
Company’s operational strategies and planning, and driving
continued progress towards the commercialization of eptinezumab.
She will report to Paul B. Cleveland, Interim President and Chief
Executive Officer.
Ms. Lavelle most recently served as the General Manager of
Amgen’s Taiwan affiliate, where she was responsible for managing a
portfolio of six commercialized products and leading a team of 80
cross-functional colleagues. Prior to that role, Ms. Lavelle was
based in Hong Kong as an Executive Director for the Japan
Asia-Pacific region, leading Commercial Excellence and Digital
Health, where she was responsible for establishing the business
analytics team, the brand strategy process and the region’s
governance model during the region’s initial build. Prior to that,
she held roles as Executive Director in the areas of Global
Marketing, Global Commercial Finance and Strategy, and Corporate
Development. Ms. Lavelle began her career in 1998 as an investment
banker in the healthcare group at Merrill Lynch & Co. Ms.
Lavelle holds a Bachelor of Arts in Economics from Yale
University.
“We are very pleased to have Erin join the Alder team and look
forward to benefiting from her experience implementing strategic
and operational initiatives to drive commercial development as we
enter the next phase of Alder’s growth,” said Mr. Cleveland. “Erin
brings a proven track record of managing complex operations within
the biopharmaceutical industry, and her appointment to the
newly-created COO role is another significant step in Alder’s
process to build out our team with talented leaders to ensure we
are well-positioned for a successful commercialization of
eptinezumab.”
“I am excited to join Alder at such an important point in the
Company’s path toward commercialization,” said Ms. Lavelle.
“Eptinezumab represents a meaningful opportunity to transform
treatment for migraine patients, and I look forward to working
alongside Alder’s talented team of scientists, physicians and
employees.”
About Alder BioPharmaceuticals, Inc.Alder
BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical
company committed to transforming the treatment paradigm for
patients with migraine and other serious neurological or
inflammatory conditions. Leveraging its pioneering monoclonal
antibody technologies, Alder discovers and develops novel
therapeutic antibodies designed to deliver highly differentiated,
best-in-class clinical profiles. Alder's lead pivotal-stage product
candidate, eptinezumab, is being evaluated as potentially the
first-to-market migraine prevention infusion therapy. Eptinezumab
is a monoclonal antibody (mAb) inhibiting calcitonin gene-related
peptide (CGRP), which is believed to play a key role in mediating
and initiating migraine. Alder is additionally evaluating ALD1910,
a preclinical product candidate also in development as a migraine
prevention therapy. ALD1910 is a monoclonal antibody that inhibits
pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38),
another protein that is active in mediating the initiation of
migraine. Clazakizumab, Alder's third program, is a monoclonal
antibody candidate that inhibits interleukin-6 and is licensed to
Vitaeris, Inc. For more information, please visit
http://www.alderbio.com.
Forward-Looking StatementsThis press release
contains forward-looking statements, including, without limitation,
statements relating to: the continued build-out of Alder’s
executive team; Alder’s growth and development; the role of Alder’s
Chief Operating Officer; the continued development and clinical,
therapeutic and commercial potential of eptinezumab; the
opportunity of eptinezumab to transform treatment for migraine
patients; and the anticipated commercialization of
eptinezumab. Words such as “continues,” “build,” “position,”
“next,” “growth,” “development,” “will,” “progress,” “look
forward,” “drive,” “towards,” “step,” “well-positioned,”
“opportunity,” or other similar expressions, identify
forward-looking statements, but the absence of these words does not
necessarily mean that a statement is not forward-looking. In
addition, any statements that refer to expectations, projections or
other characterizations of future events or circumstances are
forward-looking statements. The forward-looking statements in this
press release are based upon Alder's current plans, assumptions,
beliefs, expectations, estimates and projections, and involve
substantial risks and uncertainties. Actual results and the timing
of events could differ materially from those anticipated in the
forward-looking statements due to these risks and uncertainties as
well as other factors, which include, without limitation: the
uncertain timing of, and risks relating to, the executive search
process; risks related to the potential failure of eptinezumab to
demonstrate safety and efficacy in clinical testing; Alder's
ability to conduct clinical trials and studies of eptinezumab
sufficient to achieve a positive completion; the availability of
data at the expected times; the clinical, therapeutic and
commercial value of eptinezumab; risks and uncertainties related to
regulatory application, review and approval processes and Alder's
compliance with applicable legal and regulatory requirements; risks
and uncertainties relating to the manufacture of eptinezumab;
Alder's ability to obtain and protect intellectual property rights,
and operate without infringing on the intellectual property rights
of others; the uncertain timing and level of expenses associated
with Alder’s development and commercialization activities; the
sufficiency of Alder's capital and other resources; market
competition; changes in economic and business conditions; and other
factors discussed under the caption "Risk Factors" in Alder's
Annual Report on Form 10-K for the fiscal year ended December 31,
2017, which was filed with the Securities and Exchange Commission
(SEC) on February 26, 2018, and is available on the SEC's website
at www.sec.gov. Additional information will also be set forth in
Alder's other reports and filings it will make with the SEC from
time to time. The forward-looking statements made in this press
release speak only as of the date of this press release. Alder
expressly disclaims any duty, obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in Alder's expectations with
regard thereto or any change in events, conditions or circumstances
on which any such statements are based.
Investor Relations Contact:Ashwin AgarwalVice
President, Corporate StrategyAlder Biopharmaceuticals,
Inc.425-408-8567aagarwal@alderbio.com
Michael SchaffzinStern Investor Relations,
Inc.212-362-1200michael@sternir.com
Media Contact:Andy Brimmer / Aura Reinhard /
Trevor GibbonsJoele Frank, Wilkinson Brimmer
Katcher212-355-4449
Alder BioPharmaceuticals (NASDAQ:ALDR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alder BioPharmaceuticals (NASDAQ:ALDR)
Historical Stock Chart
From Apr 2023 to Apr 2024